DOP076 A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis

Bruce E. Sands, Colleen Marano, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2017

Cited by 1